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Abstract
Background: XPC is involved in the nucleotide excision repair of DNA damaged by carcinogens known to cause
bladder cancer. Individuals homozygous for the variant allele of XPC c.1496C > T (p.Ala499Val) were shown in a
large pooled analysis to have an increased bladder cancer risk, and we found two 3’UTR variants, *611T > A and c.
*618A > G, to be in strong linkage disequilibrium with c.1496T. Here we determined if these two 3’UTR variants
can affect mRNA stability and assessed the impact of all three variants on mRNA and protein expression.
Methods: In vitro mRNA stability assays were performed and mRNA and protein expression measured both in
plasmid-based assays and in lymphocytes and lymphoblastoid cell lines from bladder and breast cancer patients.
Results: The two 3’UTR variants were associated with reduced protein and mRNA expression in plasmid-based
assays, suggesting an effect on mRNA stability and/or transcription/translation. A near-significant reduction in XPC
protein expression (p = 0.058) was detected in lymphoblastoid cell lines homozygous for these alleles but no
differences in mRNA stability in these lines was found or in mRNA or protein levels in lymphocytes heterozygous
for these alleles.
Conclusion: The two 3’UTR variants may be the variants underlying the association of c.1496C > T and bladder
cancer risk acting via a mechanism modulating protein expression.
Background
Transitional cell carcinoma of the bladder is the fourth
commonest cancer in men in the United Kingdom (http://
info.cancerresearchuk.org/cancerstats/types/bladder/index.
htm) with cigarette smoking and occupational chemical
exposure being major risk factors. The metabolism of such
carcinogens generates many bulky DNA adducts which
are repaired by the nucleotide excision repair (NER) path-
way [1]. A key NER protein, XPC, recognizes and binds to
helix-distorting DNA adducts [2] and is involved in repair
of oxidative DNA damage formed following carcinogen
exposure [3].
We previously studied 23 XPC SNPs in 547 bladder
cancer cases and 579 controls, and found that
homozygous carriage of the variant alleles of c.1496C > T
(p.Ala499Val, rs2228000) and two 3’-untranslated region
(UTR) polymorphisms, c.*611T > A (rs2470352) and
c.*618A > G (rs2470458; previously named Ex15-184 and
Ex15-177 respectively), was associated with increased
bladder cancer risk [4]. Recently the effect of the c.1496T
variant has been confirmed in a large pooled analysis [5].
However, this variant is not predicted to have functional
effects by a number of analytical tools, and in support of
this, we recently demonstrated that the c.1496 T allele
had no influence on recruitment of GFP-tagged XPC to
sites of focal 408 nm laser damage in a cell-based assay
[6]. We therefore wished to determine whether the two
3’UTR variants in strong linkage disequilibrium with
c.1496T had an impact on mRNA stability and mRNA
and protein expression, thus potentially being the var-
iants underlying the association between c.1496T and
increased bladder cancer risk.
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Cell lines
Cells were grown at 37°C in a 5% CO2 humidified atmo-
sphere. Lymphoblastoid cell lines (LCLs) established
from breast cancer patients [7] were cultured in RPMI
1640, 15% heat inactivated fetal bovine serum (FBS), 1%
L-glutamine + penicillin/streptomycin. GM15983 SV40-
transformed XP-C cells (2 bp frameshift at codon 431,
purchased from the Coriell Institute, NJ) [8], were cul-
tured in Dulbecco’s Modified Eagle’s Medium (Sigma),
10% FBS and 1% L-glutamine. Daudi human lympho-
blastoid cells, purchased from ATCC, and RT112M
bladder cancer cells were cultured in RPMI 1640, 10%
FBS, 1% L-glutamine.
3’UTR plasmid reporter system and FACS analysis
The plasmid reporter system and analysis has been
described in detail [6]. Briefly, the 5’-a n d3 ’UTR regions
of XPC were cloned into plasmid pTH-GFPa and the
changes c.*611T > A and c.*618A > G introduced by site-
directed mutagenesis. Plasmids were transfected into
RT112 bladder cancer cells, using Fugene transfection
reagent and cells analysed by FACS for mean fluorescent
intensity (MFI) after overnight incubation. RNA was iso-
lated from parallel cultures and used to synthesise cDNA
for quantitative real-time RT-PCR with SYBR green as
the fluorescent reporter, to determine the Ct value, and
GFP mRNA quantified relative to the housekeeping gene
36B4.
XPC mRNA stability assays
BCL and GM15983 cells were plated into 6-well tissue cul-
ture plates and 24-hours later treated with actinomycin D
(ActD, 1 μg/ml) (Sigma, UK). Cells were harvested at 0
(control, untreated), 2, 4, 6 and 8 hours later and total
RNA was extracted using a PerfectPure RNA Cultured
Cell Kit (Flowgen Bioscience, Nottingham, UK) and used
to synthesize cDNA using Superscript II (Invitrogen, UK).
XPC mRNA was quantified using quantitative real-time
RT-PCR (Table 1), with XPC cDNA levels normalized to
SDHA.
Patient sample collection and processing
Local ethical approval was granted by the Leeds Teach-
ing Hospitals Local Research Ethics Committee (LREC)
and informed consent obtained. A 20 ml blood sample
was collected from 49 patients with a previous history
of bladder cancer.
DNA preparation and sequencing
Genomic DNA was isolated from 200 μl whole blood from
bladder cancer patients using a QIAamp DNA Micro Kit
(Qiagen). PCR reactions were carried out in a total volume
of 20 μlc o n t a i n i n g2 0n go fD N A ,1 0μlH o t s t a r T a q
Master Mix (Qiagen), and 0.5 μM forward and reverse pri-
mers (Table 2). Thermal cycling parameters were 15 min
at 95°C, followed by 45 cycles of 95°C for 30 seconds, opti-
mal primer annealing temperature for 30 seconds and
72°C for 30 seconds, followed by a final extension of 72°C
for 10 minutes. The PCR products were Sanger sequenced
using ABI BigDye Terminator (Applied Biosystems, USA)
and compared to the reference sequence (GenBank acces-
sion number AC090645).
RNA extraction and quantitative real-time RT-PCR
Peripheral blood mononuclear cells (PBMC) from bladder
cancer patients were isolated from 19.8 ml whole periph-
eral blood using Lymphoprep™ tubes (Greiner Bio-one
Ltd, Brunel Way, UK) with Ficoll gradient centrifugation.
The cells were then incubated at 37°C/5% CO2 in RPMI
1640, 10% heat-inactivated FBS, 1% phytohemagglutinin
(Sigma) for 72 hours. Total RNA was extracted using the
PerfectPure RNA Blood Kit (Flowgen Bioscience, Notting-
ham, UK) and used to synthesize cDNA using Superscript
II (Invitrogen, UK). For the LCLs, total RNA was extracted
similarly, after cells were grown in RPMI 1640 with 10%
heat-inactivated FBS, at 37°C/5% CO2 for 3-5 days.
mRNA levels were quantified using gene-specific primer
pairs by real-time RT-PCR (Table 1) on a 7500 Real Time
PCR System using SYBR Green I (Applied Biosystems,
CA). PCR reactions were performed using 5 μlc D N A
(corresponding to 50 ng RNA), 300 pM primers and SYBR
Green matrix (AB Applied Biosystems, CA) per reaction in
triplicates of 25 μl volume, following the manufacturer’s
protocol. Thermal cycling parameters were 50°C for
2 min, denaturation at 95°C for 10 min, then 40 cycles of
amplification (95°C for 15 seconds and annealing/exten-
sion at 60°C for 1 min). Results were analyzed using the
comparative Ct method after validation, with XPC cDNA
levels normalized to those of SDHA.
Protein extraction and western blotting
The LCLs and PHA-stimulated PBMC from bladder
cancer patients were lysed in RIPA buffer, containing
1% protease and phosphatase inhibitors (Sigma, UK),
the lysate clarified by centrifugation and stored at -80°C.
Table 1 Primers for real-time RT-PCR
Primer Assay Primer Sequences Direction
XPC-F XPC 5’-TACTCCCATCCCGTGACT-3’ Forward
XPC-R XPC 5’-GAGCCCGCTTCTCCTTT-3’ Reverse
SDHA-F SDHA 5’-TGGGAACAAGAGGGCATCTG-3’ Forward
SDHA-R SDHA 5’-CCACCACTGCATCAAATTCATG-3’ Reverse
GFP-F GFP 5’-CAACCACTACCTGAGCACCCAGTC-3’ Forward
GFP-R GFP 5’-GGCGGCGGTCAGGAACTC-3’ Reverse
36B4-F 36B4 5’-GAAACTCTGCATTCTCGCTTCC-3’ Forward
36B4-R 36B4 5’-GATGCAACAGTTGGGTAGCCA-3’ Reverse
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utes, resolved on 7.5% or 10% (w/v) polyacrylamide Tris
gels and transferred onto Hybond-C membrane (Amer-
sham, Little Chalfont, UK) at 100 V for 1 h in ice-cold
transfer buffer (25 mM Tris, 192 mM glycine). Follow-
ing blocking in Odyssey blocking buffer (Li-cor Bios-
ciences, Cambridge, UK) for 1 h, blots were incubated
for 1 h in antibody buffer [1:1 v/v Odyssey blocking buf-
fer: phosphate buffered saline, 0.1% v/v Tween-20 (PBS-
T)] containing primary antibody: XPC 1:1,000 (rabbit
polyclonal C-terminal anti-XPC, Sigma, UK) or b-actin
1:10,000 (mouse monoclonal clone AC-15, Sigma, UK).
After three 20 min washes in PBS-T, blots were incu-
bated with secondary antibody (1:5,000; 680-conjugated
goat anti-rabbit IgG (Invitrogen, Paisley, UK) or IRDye
800-conjugated rabbit anti-mouse IgG (Rockland, Peter-
borough, UK)). Following three washes in PBS-T, XPC
protein was detected and quantified using the Odyssey
infra-red detection system (Li-cor Biosciences UK Ltd,
Cambridge, UK) and bands normalized to b-actin levels.
Statistical analysis
All statistical analyses were performed using Excel and
SPSS software. Student’s t-test was used for comparison
of means. Pair-wise correlations between the relative
expressions levels were analyzed by the Pearson correla-
tion coefficient. P values < 0.05 were considered statisti-
cally significant.
Results
We used a plasmid based assay, in which the individual
3’UTR variants (Figure 1A) were transfected into
RT112 bladder cancer cells to assess their impact on
the relative protein expression assayed by FACS and
relative mRNA content assayed by quantitative real-
time RT-PCR (Figure 1B, C and Table 3. There were
significant reductions in both protein (p = 0.03) and
mRNA expression (p = 0.01) in the presence of either
3’UTR SNP variant compared to those of wild-type
3’UTR.
In order to assess whether these variants modified the
endogenous mRNA and protein levels we made use of
LCLs established from blood samples from six breast
cancer patients (BCLs), who had been genotyped pre-
viously for the three SNPs of interest and found to be
either wild-type (three lines) or carriers of the variant
alleles (three lines) (Hall and Vaslin, unpublished data).
We examined the median mRNA levels in the two
panels of BCLs and found a lower level in the homozy-
gous compared to the wild-type lines although the result
was not statistically significant (p = 0.49), with a wide
interquartile range observed (Figure 2A). There was a
borderline-significant reduction (p = 0.058) in median
protein level in the homozygous carriers of the variant
alleles compared to carriers of the wild-type alleles (Fig-
ure 2B and see Figure 2C for representative western
blots). RNA stability was then assessed, by quantifying
the transcript level at different times after the addition
of Actinomycin D to the culture medium to arrest tran-
scription, with mRNA quantified by quantitative RT-
PCR (Figure 2D). Although mRNA decay was initially
more rapid in the wild-type cells, mRNA levels appeared
lower at 6 hours in homozygous mutant lines. However,
the differences were not statistically significant (p = 0.21).
We then compared mRNA and protein levels with the
genotype in bladder cancer patients whom we re-
approached from our previous case-control study. Forty-
nine hospital patients gave a blood sample (two samples
in the case of one individual), and results were obtained
for 46 individuals. Thirty samples were wild-type for all
three variants (c.1496C > T, c.*611T > A and c.*618A
> G), 16 were heterozygous for all three, and one was
heterozygous for c.1496C > T but wild-type for c.*611T
> A and c.*618A > G. There was no significant differ-
ence in median XPC protein expression or median
mRNA level between lymphocytes from wild-type and
heterozygous individuals (p = 0.12 and p = 0.29 respec-
tively, Figure 2A and 2B).
Discussion
The XPC SNP c.1496C > T (p.Ala499Val) is associated
with increased bladder cancer risk [4,5]. However,
c.1496C > T is not predicted to have functional effects
by the analytical software tools SIFT (http://sift.jcvi.org/
), Polyphen (http://genetics.bwh.harvard.edu/pph2/) and
Pfam (http://pfam.sanger.ac.uk) and, compatible with
the prediction software results, we recently found no
effect of c.1496T on recruitment of XPC to sites of 408
nm laser microbeam damage [6]. However, individual
SNPs can themselves be functional or alternatively in
linkage disequilibrium with other variants which are
causal [9] and we previously found the two 3’UTR XPC
Table 2 XPC primers, amplicon size and annealing temperatures
SNPs Forward primer sequence Reverse primer sequence Amplicon size (bp) Annealing temp (°C)
c.1496C > T GACAAGCAGGAGAAGGCAAC ACCATCGCTGCACATTTTCT 333 63
c.*611T > A
c.*618A > G
AATGCGCTGATCGTTTCTT AGAGCCAAATCTTTAGATAAATGC 420 61
Primer pairs designed based on the XPC sequence (GenBank accession number AC090645).
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5’ UTR GFP CODING REGION 3’ UTR
611 618 CMV promoter
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611 618 CMV promoter
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611 618 CMV promoter
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C.*611T>A
C.*618A>G
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p=0.01 p=0.01
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Relative Mean Fluorescent Intensity
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B)
Figure 1 3’UTR plasmid reporter assay. A) Schematic diagram of pTH-GFPa constructs used in mRNA translational efficiency assays. B) 3’UTR
plasmid reporter system and FACS analysis (n = 3, duplicate wells analysed in each experiment, 2-tailed t-test, error bars SD); (i) Mean
fluorescence intensity (MFI) of RT112 cells transfected with GFP-flanked by mutant 3’UTR sequences relative to that of GFP-flanked by wild-type
XPC UTR sequences; (ii) Relative levels of GFP mRNA to 36B4 mRNA analysed by quantitative RT-PCR using the ΔΔCt method. C) Flow cytometry
data of individual transfections (n = 3, duplicate wells analysed in each experiment). GFP fluorescence measured on × axis (forward scatter on y
axis). See Table 3 for mean fluorescent intensity values.
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Page 4 of 7Table 3 Mean Fluorescent Intensity (MFI) of GFP transfected cells
Expt1 Mean
MFI
% Expt2 Mean MFI % Expt3 Mean
MFI
% Mean %
(± StDev)
Wild Type 3577 4145.5 100 5736 6165.5 100 3953 4135.5 100 100
4706 6595 4334
*611T > A 2541 2735 66.04 4196 4469 72.48 2168 2059 49.69 62.74
(± 11.75)
2929 4742 1950
*618A > G 3681 3066 74.03 3345 3832 62.15 3077 3265 78.8 71.66
(± 8.57)
2451 4319 3453
Duplicate wells were analysed in each experiment and the Wild Type MFI used as the maximum value of 100%.
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Figure 2 Breast cancer patient lymphoblastoid cell lines and bladder cancer patient clinical samples. Comparison of: A) mRNA levels, by
real time RT-PCR (n = 3), and B) XPC protein levels, by western blotting (n = 3), in LCLs from breast cancer (BR) patients and PBMC from
bladder cancer (BL) patients, with wild-type, heterozygous or homologous alleles of XPC c.1496C > T and the two 3’UTR polymorphisms (c.*611T
> A and c.*618A > G). Mean mRNA levels were normalized to SDHA and compared to that of Daudi cells. Mean protein levels were normalized
to b-actin and compared to that of Daudi cells. Thick line represents median, box represents interquartile range and errors bars represent 95%
confidence intervals. C) XPC assessment by western blotting in PBMC from some of the bladder cancer patients, with wild-type (wt) and
heterozygous (het) alleles of XPC c.1496C > T and the two 3’UTR polymorphisms (c.*611T > A and c.*618A > G). Top band only was quantified.
GM15983 cells were used as negative controls and Daudi cells were used as positive controls. D) mRNA stability assays in LCLs from breast
cancer patients and GM15983 XP-C cells. XPC mRNA levels were normalized to SDHA (n = 3, mean and SD). There was no statistically significant
difference between the curves for homozygous and wildtype LCLs at 6 hours or 8 hours.
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with c.1496C > T [4].
We therefore hypothesised that the two 3’UTR SNPs
might have an effect on XPC mRNA stability and/or
reduced mRNA transcription and/or translation, which
could explain the association of c.1496T and increased
bladder cancer risk. In this present study we demon-
strated in a plasmid-based system that, in RT112M blad-
der cancer cell lines, the two 3’UTR SNPs are each
associated with reduced protein and mRNA expression
relative to wild type. These results were compatible with
reduced mRNA stability/and or transcription. However,
when we examined the impact of these variants on endo-
genous mRNA and protein levels in a small panel of
LCLs homozygous for the wildtype or variant alleles
whilst we found a borderline significant, approximately
30%, reduction in XPC protein expression, the mRNA
expression result was more difficult to interpret as,
although there was a lower mean mRNA level in homo-
zygous carriers, there was a wide interquartile range and
the result was not statistically significant.
Using mRNA stability assays there was also a sugges-
tion of reduced stability in the LCL lines homozygous for
the variant allele, intermediate between that of LCLs car-
rying the wildtype allele and XP-C GM15983 cells, which
have undetectable mRNA and protein levels [10],
although this was not statistically significant. Clearly lar-
ger panels of cell lines are needed and it is possible that
cell type specific differences exist that means that LCLs
are not an appropriate model system. The intrinsic stabi-
lity of mRNA is determined by cis-acting sequences
located within the 3’UTR as well as trans-acting RNA
binding proteins [11]. 3’UTR SNPs may alter the binding
of these proteins or alter the secondary structure of the
3’UTR [11-13].
In terms of our bladder cancer patients, unfortunately
the terms of our ethical approval explicitly prevented us
from directly contacting patients to enrich our population
for known homozygous individuals. From our previous
study we had predicted that four of our 46 re-approached
patients would carry the homozygous genotype but, as
there were no such individuals, we could not determine
t h ee f f e c to fc a r r i a g eo ft w ov a r i a n ta l l e l e so ft h et h r e e
SNPs in our patient samples. We could only establish that
heterozygous carriage of the three variants had no influ-
ence on XPC protein or mRNA expression and so we
were unable to determine whether our in vitro findings
are replicated for endogenous XPC protein.
Conclusions
Using an in vitro assay we found that the presence of
either of the two XPC 3’-UTR SNP variants, c.*611A
and c.*618G, in strong LD with c.1496T, results in
reduced mRNA stability and protein expression. As they
are likely to either alter the structure of the 3’UTR or
alter the binding of RNA binding proteins, it is perhaps
not surprising that both exhibit similar phenotypes as
they are only seven base pairs apart, and may be the
causal variants that explain the associations previously
found for c.1496T with increased bladder cancer risk.
Abbreviations
ActD: actinomycin D; BCL: breast cancer lymphoblastoid cell lines; FBS: fetal
bovine serum; LCLs: lymphoblastoid cell lines; LREC: Local Research Ethical
Committee; MFI: mean fluorescent intensity; NER: nucleotide excision repair;
SNPs: single nucleotide polymorphisms; UTR: untranslated region.
Acknowledgements
This work was supported by Cancer Research UK [C6228/A7625, C15140/
A7298 and C5255/A12678, AEK] and Yorkshire Cancer Research [L304, AEK].
We thank Thomas Hughes for help with the mRNA assays and Mark Teo for
running the prediction tools software.
Author details
1Section of Experimental Oncology, Leeds Institute of Molecular Medicine,
Leeds LS9 7TF, UK.
2Section of Experimental Oncology, Leeds Institute of
Molecular Medicine, Leeds LS9 7TF, UK.
3Section of Epidemiology and
Biostatistics, Leeds Institute of Molecular Medicine, Leeds LS9 7TF, UK.
4INSERM U612, Centre Universitaire, Orsay 91405, France and Institut Curie,
Centre Universitaire, Orsay 91405, France.
5Section of Experimental Oncology,
Leeds Institute of Molecular Medicine, Leeds LS9 7TF, UK.
6INSERM U612,
Centre Universitaire, Orsay 91405, France and Institut Curie, Centre
Universitaire, Orsay 91405, France.
7Section of Epidemiology and Biostatistics,
Leeds Institute of Molecular Medicine, Leeds LS9 7TF, UK.
8Section of
Experimental Oncology, Leeds Institute of Molecular Medicine, Leeds LS9
7TF, UK.
9Section of Experimental Oncology, Leeds Institute of Molecular
Medicine, Leeds LS9 7TF, United Kingdom and Gray Institute for Radiation
Oncology and Biology, Department of Oncology, University of Oxford OX3
7DQ, UK.
Authors’ contributions
BQ designed and performed the mRNA and protein assays and mRNA
stability assays and wrote the first draft of the manuscript.
GBS designed and performed the 3’UTR plasmid reporter assays and wrote
the relevant sections of the manuscript. FE checked the statistical analysis
and reviewed the manuscript for statistical content. LV genotyped the breast
cancer patient lymphoblastoid cell lines.
JB supervised the experimental work and advised on experimental design,
and edited the manuscript. JH provided the breast cancer patient
lymphoblastoid cell lines and redrafted and edited the manuscript. DTB
reviewed and edited the manuscript. MAK provided RT112 cell lines and
edited the manuscript. AEK designed the study, recruited the bladder cancer
patients and drew their blood samples, supervised the experimental work,
and redrafted the manuscript. All authors reviewed and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 April 2011 Accepted: 20 June 2011 Published: 20 June 2011
References
1. Friedberg EC: How nucleotide excision repair protects against cancer. Nat
Rev Cancer 2001, 1:22-33.
2. Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP,
Hanaoka F, Bootsma D, Hoeijmakers JH: Xeroderma pigmentosum group
C protein complex is the initiator of global genome nucleotide excision
repair. Mol Cell 1998, 2:223-232.
3. D’Errico M, Parlanti E, Teson M, de Jesus BM, Degan P, Calcagnile A,
Jaruga P, Bjoras M, Crescenzi M, Pedrini AM, Egly JM, Zambruno G,
Stefanini M, Dizdaroglu M, Dogliotti E: New functions of XPC in the
Qiao et al. BMC Medical Genetics 2011, 12:84
http://www.biomedcentral.com/1471-2350/12/84
Page 6 of 7protection of human skin cells from oxidative damage. EMBO J 2006,
25:4305-4315.
4. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE: Comprehensive analysis of
22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol
Biomarkers Prev 2006, 15:2537-2541.
5. Stern MC, Lin J, Figueroa JD, Kelsey KT, Kiltie AE, Yuan JM, Matullo G,
Fletcher T, Benhamou S, Taylor JA, Placidi D, Zhang ZF, Steineck G,
Rothman N, Kogevinas M, Silverman D, Malats N, Chanock S, Wu X,
Karagas MR, Andrew AS, Nelson HH, Bishop DT, Sak SC, Choudhury A,
Barrett JH, Elliot F, Corral R, Joshi AD, Gago-Dominguez M, Cortessis VK,
Xiang YB, Gao YT, Vineis P, Sacerdote C, Guarrera S, Polidoro S, Allione A,
Gurzau E, Koppova K, Kumar R, Rudnai P, Porru S, Carta A, Campagna M,
Arici C, Park SS, Garcia-Closas M: International Consortium of Bladder
Cancer: Polymorphisms in DNA repair genes, smoking, and bladder
cancer risk: findings from the international consortium of bladder
cancer. Cancer Res 2009, 69:6857-6864.
6. Qiao B, Ansari AH, Scott GB, Sak SC, Chambers PA, Elliott F, Teo MT,
Bentley J, Churchman M, Hall J, Taylor CF, Bishop TD, Knowles MA, Kiltie AE:
In vitro functional effects of XPC gene rare variants from bladder cancer
patients. Carcinogenesis 2001, 32:516-21.
7. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J:
Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and
response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003,
12:1168-1174.
8. Li L, Bales ES, Peterson CA, Legerski RJ: Characterization of molecular
defects in xeroderma pigmentosum group C. Nat Genet 1993, 5:413-417.
9. Ioannidis JP, Thomas G, Daly MJ: Validating, augmenting and refining
genome-wide association signals. Nat Rev Genet 2009, 10:318-329.
10. Emmert S, Kobayashi N, Khan SG, Kraemer KH: The xeroderma
pigmentosum group C gene leads to selective repair of cyclobutane
pyrimidine dimers rather than 6-4 photoproducts. Proc Natl Acad Sci USA
2000, 97:2151-2156.
11. Boffa MB, Maret D, Hamill JD, Bastajian N, Crainich P, Jenny NS, Tang Z,
Macy EM, Tracy RP, Franco RF, Nesheim ME, Koschinsky ML: Effect of single
nucleotide polymorphisms on expression of the gene encoding
thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood
2008, 111:183-189.
12. Kamiyama M, Kobayashi M, Araki S, Iida A, Tsunoda T, Kawai K, Imanishi M,
Nomura M, Babazono T, Iwamoto Y, Kashiwagi A, Kaku K, Kawamori R,
Ng DP, Hansen T, Gaede P, Pedersen O, Nakamura Y, Maeda S:
Polymorphisms in the 3’ UTR in the neurocalcin delta gene affect mRNA
stability, and confer susceptibility to diabetic nephropathy. Hum Genet
2007, 122:397-407.
13. Wang J, Pitarque M, Ingelman-Sundberg M: 3’-UTR polymorphism in the
human CYP2A6 gene affects mRNA stability and enzyme expression.
Biochem Biophys Res Commun 2006, 340:491-497.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/84/prepub
doi:10.1186/1471-2350-12-84
Cite this article as: Qiao et al.: Functional assays to determine the
significance of two common XPC 3’UTR variants found in bladder
cancer patients. BMC Medical Genetics 2011 12:84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Qiao et al. BMC Medical Genetics 2011, 12:84
http://www.biomedcentral.com/1471-2350/12/84
Page 7 of 7